Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WVE-120101 Open-Label Extension in Huntington's Disease
NCT04617847Phase 2Terminated
- Sponsor
- Wave Life Sciences
- Start
- Apr 2020
- Primary completion
- May 2021
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 7
01
Overview
A Phase 2 trial of rovanersen in Huntington's disease (HD), sponsored by Wave Life Sciences. Started Apr 2020; status: terminated.
02
Drugs
rovanersen
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT04617847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04617847.